Malin Corporation PLC Kymab and LifeArc announce strategic partnership (2147D)

TIDM0Y71

RNS Number : 2147D

Malin Corporation PLC

24 June 2019

Malin Corporation plc

Kymab and LifeArc announce strategic partnership to discover new medicines using Kymab's IntelliSelect(R) technologies

Dublin-Ireland, 24 June 2019: Malin Corporation plc. (Euronext Growth Dublin:MLC) ("Malin"), a company investing in highly innovative life sciences companies, is pleased to note that Kymab Group Limited ("Kymab"), one of Malin's Priority Assets, today announced a strategic partnership agreement with LifeArc, a leading UK medical research charity, to discover new medicines using Kymab's IntelliSelect(R) technologies.

Under the terms of the agreement, LifeArc has made an initial $10 million equity investment in Kymab, with a commitment to make an additional $20 million investment. The partnership provides LifeArc with access to Kymab's advanced suite of next generation antibody discovery technology platforms, IntelliSelect(R) . Kymab will receive a percentage of revenues that LifeArc generates from any products discovered and commercialised using Kymab's technologies.

"The Kymab-LifeArc partnership presents a unique opportunity to match Kymab's innovative antibody discovery technologies with LifeArc's ambition to advance research with direct benefits for human health, to create a new generation of medicines capable of transforming patient lives," said Darragh Lyons, Malin Chief Business & Financial Officer. "Malin believes Kymab's IntelliSelect(R) represents best-in-class technology and we are delighted that an organisation as creative and distinguished as LifeArc has recognised its capabilities and will be working alongside Kymab to drive therapeutic antibody development."

Malin owns approximately 8% of Kymab and carried its investment in Kymab at a fair value estimate of EUR28.7 million at 31 December 2018 under International Private Equity and Venture Capital Valuation guidelines.

A copy of Kymab's press release is available to view here:

https://www.kymab.com/news-and-events/news/2019/jun/24/kymab-lifearc-strategic-partnership/

On 13 May 2019, Kymab announced that it has previously confidentially submitted a draft registration statement on Form F-1 to the US Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of American Depositary Shares, each of which will represent one or a number of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.

ENDS

About Malin Corporation plc

Malin (Euronext Growth Dublin:MLC) is a company investing in and supporting highly innovative life sciences companies developing exceptional science and technology to deliver transformative outcomes for patients and create significant value for shareholders. Its purpose is to create shareholder value through the application of long-term capital and strategic support to its investee companies to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com

About Kymab

Kymab is a clinical-stage biopharmaceutical company developing a deep pipeline of novel antibody-based therapies in a broad range of indications. The Company generates its product candidates using its proprietary, integrated platforms collectively called IntelliSelect(R) . Kymab's platforms have been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies allows for the identification of antibodies with optimal drug-like properties.

About LifeArc

LifeArc is a self-funded medical research charity, its mission is to advance translation of early science into health care treatments or diagnostics that can be taken through to full development and made available to patients. It has been doing this for more than 25 years and its work has resulted in a diagnostic for antibiotic resistance and four licensed medicines. The organisation's success allows it to explore new approaches to stimulate and fund translation.

For further information please contact:

Malin

Jessica Bergin, Investor Relations & External Reporting

Tel: +353 (0)1 901 5700

investorrelations@malinplc.com

Davy Corporate Finance (Euronext Growth Adviser)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh

Tel: +44 (0)20 3709 5700

malin@consilium-comms.com

Powerscourt (Irish media enquiries)

Jack Hickey

Tel: +353 83 448 8339

malin@powerscourt-group.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCCKQDDDBKDOAB

(END) Dow Jones Newswires

June 24, 2019 07:23 ET (11:23 GMT)

Malin (LSE:0Y71)
Historical Stock Chart
From Jul 2024 to Aug 2024